Atopic dermatitis or atopic eczema is a chronic, relapsing, familial, symmetric and pruritic inflammatory skin disease that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is commonly associated with elevated serum immunoglobulin E levels and a personal or family history of allergies, allergic rhinitis and asthma.
It is one of the most common skin diseases afflicting both children and adults.
Patients with moderate-to-severe atopic dermatitis may benefit from a 52-week treatment course of dupilumab in addition to standard-of-care treatment, according to the results of the phase III LIBERTY AD CHRONOS* trial.
There is no evidence suggesting that genetically determined decrease in 25-hydroxyvitamin D (25OHD) levels confers an elevated risk of asthma, atopic dermatitis or elevated total serum immunoglobulin E (IgE), according to a recent study.
Low levels of vitamin D due to genetic polymorphism is not associated with increased risks of immune-mediated diseases such as asthma and atopic dermatitis, nor is it linked to increased total serum immunoglobulin E (IgE), in contrast to previous observations from epidemiological studies.
New drug applications approved by US FDA as of 16 - 31 March 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Repetitive, daily, high-frequency emollient therapy enhanced skin barrier integrity and function of premature and full-term neonates in communities with high relative humidity and temperature conditions, with sunflower seed oil (SSO) exhibiting a potential protective effect, according to a Nepalese study.